Shield Therapeutics plc (STX) — Cash Flow-to-Debt Ratio
Shield Therapeutics plc (STX) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of GBX-4.49 Million could theoretically repay 0% of its total liabilities (GBX76.96 Million) in one year. See STX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Shield Therapeutics plc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Shield Therapeutics plc across 11 annual periods. Also explore Shield Therapeutics plc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Shield Therapeutics plc (2014–2024)
Year-by-year debt coverage analysis for Shield Therapeutics plc. For market capitalisation and broader financial context, see Shield Therapeutics plc (STX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | GBX-7.01 Million | GBX46.95 Million | ▲ +89.4% |
| 2023 | -1.40x | GBX-37.13 Million | GBX26.49 Million | ▼ -27.9% |
| 2022 | -1.10x | GBX-18.25 Million | GBX16.65 Million | ▲ +77.9% |
| 2021 | -4.95x | GBX-16.74 Million | GBX3.38 Million | ▼ -696.6% |
| 2020 | -0.62x | GBX-1.40 Million | GBX2.25 Million | ▲ +36.2% |
| 2019 | -0.97x | GBX-4.07 Million | GBX4.17 Million | ▼ -1515.0% |
| 2018 | -0.06x | GBX-178.00K | GBX2.95 Million | ▲ +98.6% |
| 2017 | -4.29x | GBX-16.15 Million | GBX3.76 Million | ▼ -66.9% |
| 2016 | -2.57x | GBX-10.26 Million | GBX3.99 Million | ▼ -1222.0% |
| 2015 | -0.19x | GBX-4.18 Million | GBX21.50 Million | ▼ -12.3% |
| 2014 | -0.17x | GBX-3.34 Million | GBX19.29 Million | — |